We are live on ! Find out more
ACM

Aisling Capital Management Portfolio holdings

AUM $472M Turnover 7.14%
1-Year Est. Return 106.83%
This Fund
S&P 500
This Quarter Est. Return
+12.93%
1 Year Est. Return
+106.83%
3 Year Est. Return
+792.82%
5 Year Est. Return
+1,009.42%
10 Year Est. Return
–
AUM
$472M
AUM Growth
-$4.67M
Cap. Flow
-$33.3M
Cap. Flow %
-7.06%
Top 10 Hldgs %
98.96%
Holding
14
New
1
Increased
–
Reduced
1
Closed
–
Avg Time Held
3.6 years
Top 10 Avg Time Held
2.9 years
Top 20 Avg Time Held
3.6 years

Top Buys

Rank Stock Value
1
VTVT icon
vTv Therapeutics
VTVT
+$1.73M

Top Sells

Rank Stock Value
1
BBIO icon
BridgeBio Pharma
BBIO
+$35M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BBIO icon
1
BridgeBio Pharma
BBIO
$13.3B
$342M 72.48%
4,589,611
-500,000
-10% -$35M
2019 Q2
28 quarters
GLUE icon
2
Monte Rosa Therapeutics
GLUE
$909M
$37.6M 7.98%
1,555,664
– –
2021 Q2
20 quarters
SNDX icon
3
Syndax Pharmaceuticals
SNDX
$1.17B
$28.8M 6.1%
1,316,806
– –
2020 Q1
25 quarters
CMPS icon
4
Compass Pathways
CMPS
$1.54B
$20.3M 4.3%
1,432,336
– –
2023 Q3
11 quarters
BCAX icon
5
Bicara Therapeutics
BCAX
$1.16B
$16.9M 3.58%
568,919
– –
2024 Q3
7 quarters
BBOT icon
6
BridgeBio Oncology
BBOT
$228M
$7.76M 1.64%
1,018,018
– –
2025 Q3
3 quarters
SRRK icon
7
Scholar Rock
SRRK
$4.9B
$4.24M 0.9%
77,031
– –
2025 Q3
3 quarters
URGN icon
8
UroGen Pharma
URGN
$1.67B
$3.97M 0.84%
108,000
– –
2025 Q4
2 quarters
BMEA icon
9
Biomea Fusion
BMEA
$60.6M
$3.01M 0.64%
2,048,757
– –
2021 Q2
20 quarters
ACRS icon
10
Aclaris Therapeutics
ACRS
$512M
$2.3M 0.49%
434,455
– –
2018 Q4
30 quarters
EPRX icon
11
Eupraxia Pharmaceuticals
EPRX
$459M
$2.15M 0.46%
325,000
– –
2026 Q1
1 quarter
VTVT icon
12
vTv Therapeutics
VTVT
$107M
$1.88M 0.4%
+50,000
New +$1.73M
2026 Q2
0 quarters
MRKR icon
13
Marker Therapeutics
MRKR
$20M
$478K 0.1%
325,370
– –
2018 Q4
30 quarters
OKUR icon
14
OnKure Therapeutics
OKUR
$91.1M
$404K 0.09%
88,607
– –
2021 Q2
20 quarters

Similar funds

LSA
Lansing Street Advisors Ambler, Pennsylvania $472M AUM 23.5% 1-Year Est. Return
AWA
Acumen Wealth Advisors Chattanooga, Tennessee $472M AUM
PWM
Paulson Wealth Management Wheaton, Illinois $471M AUM 22.04% 1-Year Est. Return
SWRP
Summit Wealth & Retirement Planning San Ramon, California $472M AUM 25.49% 1-Year Est. Return
CFLC
California First Leasing Corp Newport Beach, California $471M AUM 182.74% 1-Year Est. Return
DBRC
D.B. Root & Company Pittsburgh, Pennsylvania $471M AUM 19.62% 1-Year Est. Return
HNWAG
High Net Worth Advisory Group Naples, Florida $471M AUM 22.07% 1-Year Est. Return
AIM
AMI Investment Management Kendallville, Indiana $471M AUM 14.02% 1-Year Est. Return

Aisling Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Aisling Capital Management held 14 positions worth $472M, down 0.98% from $476M the previous quarter. Its ten largest holdings account for 99% of the portfolio.

Aisling Capital Management withdrew a net $33.3M in Q2 2026, reducing 1 holding. Its largest reduction was BridgeBio Pharma, cutting an estimated $35M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Aisling Capital Management opened a new position in vTv Therapeutics worth $1.88M.

  • Aisling Capital Management's largest Q2 2026 buy was vTv Therapeutics: 50,000 shares worth $1.88M.
  • Aisling Capital Management's biggest Q2 2026 reduction was BridgeBio Pharma, cutting an estimated $35M.
  • Aisling Capital Management's ten largest holdings make up 99% of its $472M portfolio in Q2 2026.
  • Aisling Capital Management opened 1 new position and closed 0 in Q2 2026.
  • Aisling Capital Management's portfolio value fell 0.98% quarter-over-quarter to $472M.

Based on Aisling Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.